Silence Therapeutics plc
Divesiran
Polycythemia Vera
Date
TBD
Approval decision · Date TBD estimated
What's at stake
A final FDA approval decision on Divesiran for Polycythemia Vera is expected Date TBD.
Primary source
· SEC 8-K
verified 15h ago
“Treatment goal is to control HCT <45% to reduce CV and major thrombotic events”